Boule Diagnostics signs an exclusive distribution agreement for CRP diagnostics on the US market

Boule Diagnostics AB has signed agreements with Finnish company Orion Diagnostica Oy to launch and market CRP testing systems in the USA. Boule will have exclusive distribution rights on the US market to the QuikRead® go CRP, which is manufactured by Orion. The product is expected to go on sale in the second half of 2016, when it has been registered and received US Food and Drug Administration (FDA) approval for marketing.

C Reactive Protein (CRP) testing is used in Sweden to e.g. determine if a patient with symptoms has some infection or an inflammation in their body. Overuse of antibiotics in the western world is a big problem and CRP testing can give doctors a better idea of whether or not antibiotic treatment is necessary.

“We are very cautious about introducing external products into our distribution network, but in this case we are both proud and delighted to welcome Orion as a partner. Orion is a world-leader in point-of-care CRP diagnostics and we look forward to launching the QuikRead® go CRP in the USA, the world’s largest market for in-vitro diagnostics. What’s more, point-of-care CRP diagnostics is probably one of the most logical complements to our own products,” says Ernst Westman, President and CEO, Boule Diagnostics AB.

“We chose Boule as our business partner in the USA as they have an excellent distribution network and a brand that is renowned for quality and confidence on the American market,” says Gabriella von Flittner, Vice President, Marketing, Orion Diagnostica Oy.

For more information, please contact:

Ernst Westman, President and CEO Boule Diagnostics AB, tel +46 708 60 88 63

About Boule Diagnostics AB (publ) 

Boule Diagnostics AB is a rapidly growing diagnostics company that develops, manufactures and markets systems and consumables for blood cell counts (hematology) outpatient care. The company is primarily oriented to small and medium sized hospitals, clinics and laboratories within outpatient care, and to other diagnostics companies within both human and veterinary hematology. The company operates via subsidiary operating companies in Sweden, USA and China. Boule Diagnostics shares have been listed on the NASDAQ OMX Stockholm Exchange since 2011.

About Orion Diagnostica Oy

Orion Diagnostica Oy (Espoo, Finland) is part of the Orion Group, the leading healthcare company in Finland. Orion Diagnostica develops, manufactures and markets diagnostic tests. It specializes in easy-to-use, cost-effective clinical in-vitro diagnostic tests and hygiene monitoring solutions designed to improve healthcare effectiveness and individual well-being. Its special focus is on products for primary healthcare that enable consultation, testing and treatment decisions to be completed during a single patient visit.

Boule Diagnostics AB is required to publish the information in this press release by the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information is embargoed for publication until 08:30 (CET) on 21/12/2015.


  • Subscribe to our news